MedTrace Logo

Efficacy and Safety of Panlongqi Tablet in Patients With Knee Osteoarthritis

NCT03327012 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2017-10-31

No results posted yet for this study

Summary

This study evaluates the efficacy and safety of Panlongqi tablet compared with placebo in the treatment of knee osteoarthritis in adults.Half of participants will receive Panlongqi tablet in combination,while the other half will receive a Placebo.

Conditions

Interventions

DRUG

Treatment of Panlongqi Tablet

Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.

DRUG

Treatment of Panlongqi placebo

Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.

Sponsors & Collaborators

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Jiang Quan, Doctor · Guang'anmen Hospital of China Academy of Chinese Medical Sc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2019-03-28
Completion
2019-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03327012 on ClinicalTrials.gov